

## **Modus Therapeutics to present sevuparin data at the European Iron Club Meeting 2026 in Dublin**

Stockholm, May 21, 2026 – Modus Therapeutics Holding AB (“Modus” or the “Company”) today announces that an abstract based on the Company’s preclinical research on sevuparin has been accepted for oral presentation at the European Iron Club Meeting 2026 (EIC 2026), taking place at Trinity College, Dublin, on 18–20 June 2026.

The presentation will be delivered by **Dr Michela Asperti**, previously a researcher in Professor Maura Poli’s team at the University of Brescia and now affiliated with University eCampus (Novedrate), and author of several publications on sevuparin’s hepcidin-lowering effects, including Asperti et al., *HemaSphere* 2024.

The European Iron Club is one of Europe’s leading scientific forums for research on iron metabolism and iron-related diseases, gathering internationally recognised scientists and clinicians in the field. Acceptance for an oral presentation reflects peer review and recognition of high scientific quality and relevance.

**Title of presentation:** *Therapeutic potential of sevuparin in chronic kidney disease anaemia: synergistic effects with EPO and molecular insights into renal protection.*

**Session:** Saturday 20 June, 15:10–15:25, as part of plenary session 6, “Emerging Approaches to Modernising Iron Medicine”.

### **About sevuparin and hepcidin**

Sevuparin is a proprietary heparin derivative engineered to retain essentially no anticoagulant activity while exhibiting potent hepcidin-suppressing effects. Hepcidin is important for regulating the iron homeostasis of the body, and elevated hepcidin levels driven by inflammation are a key mechanism underlying anaemia in chronic kidney disease (CKD with anaemia) and other inflammatory conditions. Sevuparin acts by suppressing hepcidin elevation driven by both basal iron-regulatory (BMP/SMAD) and inflammatory (IL-6) pathways, which constitutes a mechanism of action that is differentiated from erythropoiesis-stimulating agents (ESAs) and HIF-PH inhibitors.

Sevuparin is currently being evaluated in an ongoing Phase IIa study (Part 2) in Italy in patients with CKD and anaemia, with a proof-of-concept readout expected in the fourth quarter of 2026.

### **Comment from Modus**

“The acceptance of this work, conducted by Professor Maura Poli’s team in Brescia, for an oral presentation at the European Iron Club Meeting underscores the strength of the scientific foundation behind the mode of action of sevuparin. The EIC convenes the leading researchers in the iron-related disease field and is therefore a highly relevant forum in which to present our work to the scientific and clinical community central to the development of new therapies for anaemia in chronic kidney disease,” said John Öhd, CEO of Modus Therapeutics.

**For more information on Modus Therapeutics, please contact:**

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: [john.ohd@modustx.com](mailto:john.ohd@modustx.com)

**Certified Adviser**

Bergs Securities AB

Hemsida: [www.bergssecurities.se](http://www.bergssecurities.se)

**About Modus Therapeutics and sevuparin**

Modus is a Swedish biotech company developing its patented polysaccharide, sevuparin, as a treatment option for several major unmet medical needs, including anemia in kidney disease and other chronic inflammatory conditions, severe malaria, sepsis, and other disorders involving severe systemic inflammation. There is a great need for new treatments that can effectively treat these conditions. Modus’ ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at [www.modustx.com](http://www.modustx.com).

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

**Attachments**

**[Modus Therapeutics to present sevuparin data at the European Iron Club Meeting 2026 in Dublin](#)**